INTRODUCTION: Antimicrobial stewardship programmes (ASP) can reduce antibiotic use but patient safety concerns exist. We evaluated the safety of prospective carbapenem review and feedback and its impact on carbapenem use and patient outcomes. MATERIALS AND METHODS: After 3 months implementation of our ASP, we compared patients with and without acceptance of ASP recommendations on the use of carbapenems. Primary outcome was 30-day mortality. Secondary outcomes included duration of carbapenem use, length of hospitalisation, clinical response, microbiological clearance, 30-day readmission and mortality at discharge. RESULTS: Of 226 recommendations for 183 patients, 59.3% was accepted. De-escalation, switching to oral antibiotics and antibiotic cessation comprised 72% of recommendations. Patients with acceptance of ASP recommendations had lower 30-day mortality and higher end-of-therapy clinical response despite shorter carbapenem duration (P <0.05). Predictors of 30-day mortality were Pitt bacteraemia score (adjusted odds ratio [aOR] 1.39, 95% confidence interval [CI], 1.11 to 1.74; P = 0.004) and non-acceptance of ASP recommendations (aOR 2.84, 95% CI, 1.21 to 6.64; P = 0.016). CONCLUSION: Our prospective carbapenem review and feedback mainly comprising of reducing carbapenem use is safe.
INTRODUCTION: Antimicrobial stewardship programmes (ASP) can reduce antibiotic use but patient safety concerns exist. We evaluated the safety of prospective carbapenem review and feedback and its impact on carbapenem use and patient outcomes. MATERIALS AND METHODS: After 3 months implementation of our ASP, we compared patients with and without acceptance of ASP recommendations on the use of carbapenems. Primary outcome was 30-day mortality. Secondary outcomes included duration of carbapenem use, length of hospitalisation, clinical response, microbiological clearance, 30-day readmission and mortality at discharge. RESULTS: Of 226 recommendations for 183 patients, 59.3% was accepted. De-escalation, switching to oral antibiotics and antibiotic cessation comprised 72% of recommendations. Patients with acceptance of ASP recommendations had lower 30-day mortality and higher end-of-therapy clinical response despite shorter carbapenem duration (P <0.05). Predictors of 30-day mortality were Pitt bacteraemia score (adjusted odds ratio [aOR] 1.39, 95% confidence interval [CI], 1.11 to 1.74; P = 0.004) and non-acceptance of ASP recommendations (aOR 2.84, 95% CI, 1.21 to 6.64; P = 0.016). CONCLUSION: Our prospective carbapenem review and feedback mainly comprising of reducing carbapenem use is safe.
Authors: Alvin Qijia Chua; Andrea Lay-Hoon Kwa; Thean Yen Tan; Helena Legido-Quigley; Li Yang Hsu Journal: Singapore Med J Date: 2019-08 Impact factor: 1.858
Authors: Shi Thong Heng; Joshua Wong; Barnaby Young; Hui Lin Tay; Sock Hoon Tan; Min Yi Yap; Christine B Teng; Brenda Ang; Tau Hong Lee; Hui Ling Tan; Thomas W Lew; David Chien Lye; Tat Ming Ng Journal: Open Forum Infect Dis Date: 2020-06-29 Impact factor: 3.835
Authors: J F García-Rodríguez; B Bardán-García; M F Peña-Rodríguez; H Álvarez-Díaz; A Mariño-Callejo Journal: Eur J Clin Microbiol Infect Dis Date: 2018-10-26 Impact factor: 3.267
Authors: José Francisco García-Rodríguez; Belén Bardán-García; Pedro Miguel Juiz-González; Laura Vilariño-Maneiro; Hortensia Álvarez-Díaz; Ana Mariño-Callejo Journal: Antibiotics (Basel) Date: 2020-12-26
Authors: Tat Ming Ng; Shi Thong Heng; Boon Hou Chua; Li Wei Ang; Sock Hoon Tan; Hui Lin Tay; Min Yi Yap; Jason Quek; Christine B Teng; Barnaby E Young; Ray Lin; Brenda Ang; Tau Hong Lee; David C Lye Journal: JAMA Netw Open Date: 2022-05-02